Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions
AssigneesPfizer Inc., The Regents of the University of California
InventorsNatasha Kay Crellin, Lauren Kate Ely, Jason Robles Reyes, Chia Chi Ho, Jeffrey A. Bluestone, Eleonora Trotta, Qizhi Tang
Life of this patent
Estimating the term…
Abstract
The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
Claims16
An isolated polypeptide molecule that specifically binds to CD2,
- wherein the polypeptide molecule comprises an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO:
- 69, and wherein the polypeptide molecule consists of one or more substitutions at residues 36, 38, 43, 45, 77, and 86 relative to SEQ ID NO:
- 3, numbered according to SEQ ID NO:
- 3.
An isolated polypeptide that specifically binds to CD2, comprising an LFA3 domain comprising an amino acid sequence having at least about 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 17-41, wherein the LFA3 domain comprises one or more substitutions at residues 36, 38, 43, 45, 77, and 86 relative to SEQ ID NO:
- 3, numbered according to SEQ ID NO:
- 3.
An isolated polypeptide comprising an LFA3 domain,
- wherein the LFA3 domain comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:
- 3 with one or more mutations at residues 36, 38, 43 and 86, numbered according to SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.